000182621 001__ 182621
000182621 005__ 20240229145725.0
000182621 0247_ $$2doi$$a10.6004/jnccn.2022.7049
000182621 0247_ $$2pmid$$apmid:36351340
000182621 0247_ $$2ISSN$$a1540-1405
000182621 0247_ $$2ISSN$$a1540-1413
000182621 0247_ $$2altmetric$$aaltmetric:138238989
000182621 037__ $$aDKFZ-2022-02798
000182621 041__ $$aEnglish
000182621 082__ $$a610
000182621 1001_ $$0P:(DE-HGF)0$$aEyl-Armbruster, Ruth Elisa$$b0$$eFirst author
000182621 245__ $$aChange Toward Healthier Lifestyles Is Associated With Better Health-Related Quality of Life in Long-Term Colorectal Cancer Survivors.
000182621 260__ $$aCold Spring Harbor, NY$$bHarborside Press$$c2022
000182621 3367_ $$2DRIVER$$aarticle
000182621 3367_ $$2DataCite$$aOutput Types/Journal article
000182621 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1668589467_7316
000182621 3367_ $$2BibTeX$$aARTICLE
000182621 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000182621 3367_ $$00$$2EndNote$$aJournal Article
000182621 500__ $$a#EA:C070#EA:C071#LA:C071#
000182621 520__ $$aLittle is known about how changes in a constellation of lifestyle factors affect health-related quality of life (HRQoL) in colorectal cancer (CRC) survivors. Our study aimed to investigate the association between changes in healthy lifestyle and HRQoL over time in survivors of stage I-IV CRC.We included 2,283 long-term (≥5 years postdiagnosis) survivors. A healthy lifestyle score (HLS) comprising smoking, alcohol consumption, diet, physical activity, and body fatness was derived at diagnosis and 5-year follow-up (5YFU) and categorized as low, moderate, or high. We assessed HRQoL with the EORTC Quality of Life Questionnaire-Core 30 at 5YFU and 10-year follow-up. We used multivariable linear regression and linear mixed models to explore associations between changes in HLS and HRQoL over follow-up.A low baseline HLS was associated with poorer functioning and global health/QoL and a higher symptom burden at 5YFU compared with a high baseline HLS. An improved HLS from baseline to 5YFU was associated with better functioning, higher global health/QoL, and fewer symptoms at 5YFU than a maintained-high HLS. In longitudinal analyses, improved HLS was associated with better functioning at follow-up. Survivors with a maintained-high or an improved HLS reported generally less fatigue, pain, and dyspnea at follow-ups compared with survivors with a maintained-low or decreased HLS.Change toward a healthier lifestyle since diagnosis was associated with better HRQoL in long-term CRC survivors. Our results support the importance of maintaining and/or promoting a healthier lifestyle among CRC survivors postdiagnosis.
000182621 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000182621 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000182621 650_7 $$2Other$$aColorectal Cancer
000182621 650_7 $$2Other$$ahealthy lifestyle
000182621 650_7 $$2Other$$along-term survivors
000182621 650_7 $$2Other$$alongitudinal
000182621 650_7 $$2Other$$aquality of life
000182621 650_2 $$2MeSH$$aHumans
000182621 650_2 $$2MeSH$$aQuality of Life
000182621 650_2 $$2MeSH$$aHealthy Lifestyle
000182621 650_2 $$2MeSH$$aLife Style
000182621 650_2 $$2MeSH$$aSurvivors
000182621 650_2 $$2MeSH$$aColorectal Neoplasms: complications
000182621 650_2 $$2MeSH$$aSurveys and Questionnaires
000182621 7001_ $$0P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aThong, Melissa$$b1$$eFirst author$$udkfz
000182621 7001_ $$0P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aCarr, Prudence$$b2
000182621 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b3$$udkfz
000182621 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b4$$udkfz
000182621 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b5$$udkfz
000182621 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b6$$udkfz
000182621 7001_ $$0P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aArndt, Volker$$b7$$eLast author$$udkfz
000182621 773__ $$0PERI:(DE-600)2134524-7$$a10.6004/jnccn.2022.7049$$gVol. 20, no. 11, p. 1233 - 1243.e10$$n11$$p1233 - 1243.e10$$tJournal of the National Comprehensive Cancer Network$$v20$$x1540-1405$$y2022
000182621 909CO $$ooai:inrepo02.dkfz.de:182621$$pVDB
000182621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000182621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)24fe6057396bec79d2638615b12eb989$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000182621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000182621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000182621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000182621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000182621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000182621 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000182621 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000182621 9141_ $$y2022
000182621 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-02
000182621 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-02
000182621 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-16
000182621 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-16
000182621 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-16
000182621 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-16
000182621 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-16
000182621 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NATL COMPR CANC NE : 2021$$d2022-11-16
000182621 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ NATL COMPR CANC NE : 2021$$d2022-11-16
000182621 9202_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x0
000182621 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000182621 9201_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x1
000182621 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x2
000182621 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x3
000182621 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000182621 9200_ $$0I:(DE-He78)C071-20160331$$kC071$$lC071 Cancer Survivorship$$x1
000182621 980__ $$ajournal
000182621 980__ $$aVDB
000182621 980__ $$aI:(DE-He78)C070-20160331
000182621 980__ $$aI:(DE-He78)C071-20160331
000182621 980__ $$aI:(DE-He78)C120-20160331
000182621 980__ $$aI:(DE-He78)HD01-20160331
000182621 980__ $$aUNRESTRICTED